Advertisement
BNTX vs MRNA
Which Stock Would AI Choose? BioNTech SE (BNTX) vs. Moderna, Inc. (MRNA) Stock Comparison
Key Takeaways
- BNTX has absorbed a series of clinical setbacks in recent weeks, pressuring sentiment and keeping the stock in a downward trading range.
- MRNA has delivered one of the strongest biotech rallies of the year, driven by a late-stage win for its personalized cancer vaccine with Merck.
- Relative performance and momentum clearly favor MRNA, though its valuation has become significantly stretched after the surge.
- Tickeron AI Verdict: The AI currently favors MRNA over BNTX based on trend consistency, catalysts, and relative positioning.
- For more context on each name, explore BNTX Major News and BNTX Today's Price Move, as well as MRNA Major News and MRNA Today's Price Move.
- To see which automated strategies are being selected for current conditions, explore Trending AI Robots.
Introduction
BioNTech SE (BNTX) and Moderna, Inc. (MRNA) are two of the most closely watched names in the messenger RNA (mRNA) biotechnology space. Both rose to prominence on COVID-19 vaccines, and both are now attempting to prove that their mRNA platforms can extend far beyond infectious disease. This stock comparison is especially relevant for growth-oriented investors and traders assessing how two structurally similar companies are diverging in market positioning, pipeline momentum, and relative performance. While the two firms share a technology foundation, their recent trajectories have been sharply different, making the contrast between them a useful lens for evaluating risk, reward, and trend consistency in the current market environment.
BNTX Overview and Recent Performance
BioNTech SE is a German biotechnology company headquartered in Mainz that develops mRNA-based immunotherapies for cancer and infectious disease. Its best-known product is the COVID-19 vaccine it commercializes with Pfizer, a franchise whose revenue has continued to decline as pandemic-era demand normalizes. This shrinking base has weighed on BNTX, which now carries a market capitalization of roughly $22 billion and trades well below its 52-week high.
Recent market activity has been defined by pipeline volatility. The company discontinued a Phase 2 study of its personalized cancer vaccine in colorectal cancer, and separately reported that its off-the-shelf immunotherapy BNT113 did not meet its primary progression-free survival endpoint in a late-stage head and neck cancer trial. These setbacks contributed to analyst downgrades and a meaningfully weaker tone around the stock. On the positive side, BNTX reported encouraging survival data for gotistobart in lung cancer and announced that its DYNASTY-Breast02 Phase 3 trial met its primary endpoint. However, mixed results have left sentiment cautious, with the stock broadly moving lower in recent weeks as investors weigh a deep but still-unproven oncology pipeline against ongoing revenue decline.
MRNA Overview and Recent Performance
Moderna, Inc. is a Cambridge, Massachusetts-based biotechnology company that applies mRNA technology across respiratory vaccines, oncology, and rare diseases. Like BioNTech, its legacy COVID-19 business has contracted, but MRNA has spent recent weeks dramatically outperforming its peer. The catalyst was a Phase 3 success for intismeran autogene, a personalized mRNA cancer vaccine developed with Merck, which met its primary endpoint in high-risk melanoma when combined with Keytruda.
That readout triggered one of the largest single-day and year-to-date gains in the biotech sector, with MRNA surging several hundred percent on the year and briefly reaching multi-year highs. The company also received the first U.S. approval of an mRNA seasonal flu vaccine, adding another growth leg beyond COVID. More recently, the stock pulled back sharply after data release details disappointed elevated expectations and analysts trimmed ratings, underscoring how much of the company's future is now priced in. Even so, MRNA remains one of the market's clearest examples of a catalyst-driven repricing, with strong momentum but a valuation that now reflects execution risk on its emerging oncology franchise.
Trending AI Robots
For investors who prefer a data-driven, automated approach to navigating divergences like the one between BNTX and MRNA, Tickeron's Trending AI Robots page offers a curated view of the platform's AI trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and universe of securities. Because market conditions change, only a subset of these bots is well suited to the current environment, and that is precisely what the Trending AI Robots section highlights. The page is designed to surface the strategies that are best positioned right now, helping traders filter a large and diverse marketplace down to the most relevant options. To explore which automated strategies are currently being favored, visit Trending AI Robots.
Head-to-Head Comparison
Although both companies are mRNA pioneers, their current market positioning differs in important ways. BNTX retains a substantial cash position, a diversified oncology pipeline with more than two dozen mid- and late-stage programs, and a comparatively low valuation relative to its assets. Its trade-off is a declining revenue base and repeated clinical disappointments that have kept momentum weak. MRNA offers stronger near-term catalysts, a first-mover position in personalized cancer vaccines, and the benefit of a newly diversified respiratory franchise, but it carries a far richer valuation and higher expectations that leave little room for error.
In terms of risk, BNTX is exposed to execution and pipeline timing, while MRNA carries greater valuation and volatility risk after its outsized run. Sentiment has clearly favored MRNA over recent weeks, even as both names remain unprofitable on a trailing basis. The contrast ultimately comes down to momentum and catalyst quality versus valuation and balance-sheet strength.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would currently favor MRNA over BNTX. The decisive factors are trend consistency and catalyst strength: MRNA has sustained a powerful upward trend backed by a landmark late-stage oncology result, whereas BNTX has struggled to establish positive momentum amid mixed trial outcomes and declining revenue. That said, the verdict carries meaningful uncertainty, as MRNA's elevated valuation and recent pullback introduce higher downside sensitivity. The AI's preference reflects relative positioning rather than a definitive forecast, and it could shift as new data, earnings, or regulatory developments alter the balance between these two competing mRNA platforms.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNTX is a Hold and MRNA is a Hold.
BNTX in -3.13% downward trend, sliding for three consecutive days on October 26, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BNTX declined for three days, in 248 of 318 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.
Technical Analysis (Indicators)
Bearish Trend Analysis
BNTX moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNTX crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 60%.
The Aroon Indicator for BNTX entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BNTX's RSI Oscillator exited the oversold zone, 20 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 60 cases where BNTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on BNTX as a result. In 68 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for BNTX just turned positive on October 30, 2026. Looking at past instances where BNTX's MACD turned positive, the stock continued to rise in 33 of 45 cases over the following month. The odds of a continued upward trend are 73%.
Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTX advanced for three days, in 180 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
BNTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.238) is normal, around the industry mean (3.162). P/E Ratio (-13.045) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.046) is also within normal values, averaging (9.059). Dividend Yield (0.097) settles around the average of (131.622) among similar stocks. P/S Ratio (7.764) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. BNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MRNA's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for MRNA moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In 24 of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In 72 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 62 cases where MRNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
Following a +7.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 215 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 94 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.040) is normal, around the industry mean (3.104). P/E Ratio (-27.673) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BNTX | MRNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 34 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 97 | |
PRICE GROWTH RATING 1..100 | 70 | 1 | |
P/E GROWTH RATING 1..100 | 40 | 99 | |
SEASONALITY SCORE 1..100 | 31 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BNTX's Valuation (12) in the null industry is in the same range as MRNA (12) in the Biotechnology industry. This means that BNTX’s stock grew similarly to MRNA’s over the last 12 months.
BNTX's Profit vs Risk Rating (100) in the null industry is in the same range as MRNA (100) in the Biotechnology industry. This means that BNTX’s stock grew similarly to MRNA’s over the last 12 months.
BNTX's SMR Rating (93) in the null industry is in the same range as MRNA (97) in the Biotechnology industry. This means that BNTX’s stock grew similarly to MRNA’s over the last 12 months.
MRNA's Price Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for BNTX (70) in the null industry. This means that MRNA’s stock grew significantly faster than BNTX’s over the last 12 months.
BNTX's P/E Growth Rating (40) in the null industry is somewhat better than the same rating for MRNA (99) in the Biotechnology industry. This means that BNTX’s stock grew somewhat faster than MRNA’s over the last 12 months.
| BNTX | MRNA | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 74% | 1 day ago 90% |
| Stochastic ODDS (%) | 4 days ago 75% | 1 day ago 73% |
| Momentum ODDS (%) | 4 days ago 69% | 1 day ago 81% |
| MACD ODDS (%) | 4 days ago 73% | 1 day ago 88% |
| TrendWeek ODDS (%) | 4 days ago 66% | 1 day ago 79% |
| TrendMonth ODDS (%) | 4 days ago 77% | 1 day ago 80% |
| Advances ODDS (%) | 5 days ago 68% | 5 days ago 78% |
| Declines ODDS (%) | 8 days ago 78% | 1 day ago 87% |
| BollingerBands ODDS (%) | 4 days ago 74% | 1 day ago 90% |
| Aroon ODDS (%) | 4 days ago 76% | 1 day ago 72% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BNTX’s FA Score shows that 1 FA rating(s) are green while MRNA’s FA Score has 2 green FA rating(s).
- BNTX’s FA Score: 1 green, 4 red.
- MRNA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BNTX’s TA Score shows that 6 TA indicator(s) are bullish while MRNA’s TA Score has 3 bullish TA indicator(s).
- BNTX’s TA Score: 6 bullish, 4 bearish.
- MRNA’s TA Score: 3 bullish, 5 bearish.
Price Growth
BNTX (@Biotechnology) experienced а +0.06% price change this week, while MRNA (@Biotechnology) price change was +11.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.85%. For the same industry, the average monthly price growth was -13.09%, and the average quarterly price growth was -20.02%.
Reported Earning Dates
BNTX is expected to report earnings on Nov 03, 2026.
MRNA is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Biotechnology (-0.85% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BNTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BNTX has been loosely correlated with MRNA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTX jumps, then MRNA could also see price increases.
| Ticker / NAME | Correlation To BNTX | 1D Price Change % | ||
|---|---|---|---|---|
| BNTX | 100% | -1.08% | ||
| MRNA - BNTX | 60% Loosely correlated | -0.47% | ||
| CRSP - BNTX | 45% Loosely correlated | -5.23% | ||
| AXON - BNTX | 43% Loosely correlated | -2.35% | ||
| NVAX - BNTX | 42% Loosely correlated | -3.72% | ||
| MRVI - BNTX | 41% Loosely correlated | -7.68% | ||
More | ||||